Although whether or not a reduction in urinary L-FABP is commonly observed in patients with type 2 diabetes treated with SGLT2 inhibitors is unclear, patients showing a reduction in both the uACR and urinary L-FABP may have a better prognosis with regard to DKD than those without such reductions. Here, SLC5A2 is linked to type 2 diabetes mellitus.